Theranostics Health LLC is a company that was formed by George Mason University cancer researchers Dr. Lance Liotta and Emanuel Petricoin.
The company plans to tailor cancer treatments to individual patients based on proteomics, the study of proteins. Proteins play a central role in our bodies. Understanding the structure and function of each protein and its complexities of protein interactions can be critical for developing the most effective diagnostic techniques and disease treatments in the future.
Information about protein activity in tumors can allow doctors to choose the best drugs to kill the cancer cells. President and CEO of the company Joseph Reilly said "The physicians will then be provided a new class of information about that patients' individual cancer. This will enable the physician to tailor the therapy based on the individual patients' tumor."
One size fits all for cancer treatment is hopefully on its way out. We need to prescribe the right therapy to the right patient. This will increase treatment success rates and also spare patients unnecessary toxicity from chemotherapy drugs that would be unsuitable for their tumor.
